Commercial Novo hits back at rivals with cut-price Wegovy subscriptions PharmaphorumTrying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.CommercialMetabolic & GLP-1Read full story pharminent March 31, 2026 (Last updated: April 1, 2026) Pharmaphorum Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers. CommercialMetabolic & GLP-1Read full story Post navigation Previous: Lilly beefs up neuroscience pipeline with $6.3B Centessa buyoutNext: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
